About the book
Telehealth is a kind of health service via electronic information and technologies which allows clinicians to care for long-distance patients. Telehealth includes clinical and non-clinical services, such as monitoring, diagnosis, treatment, even preventative and promotive care delivery. Telemedicine is a more common term that describes remote clinical services.
From the end of 2019, the major impact caused by COVID-19 has made Telemedicine the mainstream in the coming years. This means the clinicians have to use Tele-consultation, Tele-monitoring, Tele-education, Tele-prescription, Tele-surgery, and other remote methods and technologies for disease evaluation and treatment. However, the complex nature of Telemedicine also lets us re-check whether the existing Telemedicine is sufficient to meet the higher-level medical needs in theory and practice.
Patient-Centric is that the needs for information and interaction originate from the patients. Personalized data generated by the various monitoring technologies are jointly managed by patients and medical staff. Medical staff will supervise artificial intelligence (AI) algorithm to understand the patient’s specific condition and provide the best decision-making and treatment. Thus the dream of precision medicine will come true in the future.
Based on these concepts, the book incorporates updated developments as well as future perspectives in the ever-expanding field of Telehealth / Telemedicine. Besides, this book is also a great reference for medical staff(physicians, surgeons, family doctors, ENT doctors, audiologists, psychologists, registered nurses, technologists), specialists in sleep medicine, social workers, public health practitioners, researchers in basic medicine, experts in science, students, and even patients themselves. Antibodies are the lead molecule in diagnostic and therapeutic treatment for various infectious and metabolic diseases. Since the approval of the first antibody in 1986, at present, ~100 FDA-approved antibodies are available in the market. There are several antibodies in the clinical trials and waiting for approval. The current global market for antibody-based drugs is estimated at ~ $100 billion and is projected to be ~ $200 by 2026. Although antibody-based drugs are dominating clinical applications, there are several challenges like a high production cost, short serum half-life, toxicity, immunogenicity, and limited oral drug delivery that still need to be addressed. Next-generation antibodies have unique advantages over traditional antibodies and show great potential for current limitations. The engineering of antibodies and their production host systems enable commercial production at affordable cost and quality.
This book will aim to provide broad information about antibody engineering technologies and their application to diagnostic and therapeutics for various diseases.